A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; LY 3023414 (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-238
- Sponsors Eli Lilly
- 20 Jan 2017 Planned number of patients changed from 180 to 150.
- 30 Jun 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2018.
- 30 Jun 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2018.